At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, Gastroesophageal (GE) Junction and Gastric Cancer: A Phase I Trial of ZD6474 (Zactima, Vandetanib), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
In Brief
A Phase 1 clinical trial evaluating Vandetanib, 5 Fluorouracil (FU), and 3 other interventions for Cancer of the Esophagus and 2 related conditions. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
Study Details
Timeline
Interventions
Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
Carboplatin AUC=5 days 1 and 29 during radiation therapy
Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks